Viking Therapeutics, Inc. (VKTX) — Stock Price, Chart & Analysis
Viking Therapeutics, Inc. (VKTX) is a Healthcare stock currently trading at $40.85, up 26.20% on the day. It carries a market capitalization of $4.77B. Over the past 52 weeks, VKTX has traded between $24.78 and $43.15. Viking Therapeutics, Inc. does not currently pay a regular dividend. View the live VKTX chart, technical opinion, analyst ratings, fundamentals and latest news below.
Viking Therapeutics, Inc. (VKTX) key data
| Price | $40.85 |
| Change (today) | +26.20% |
| Previous close | $32.37 |
| Market cap | $4.77B |
| EPS (TTM) | $-6.34 |
| 52-week high | $43.15 |
| 52-week low | $24.78 |
| Beta | 0.68 |
| Avg. volume | 2.29M |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about Viking Therapeutics, Inc. (VKTX)
How much does one share of Viking Therapeutics, Inc. cost?
As of the latest update, one share of Viking Therapeutics, Inc. (VKTX) trades at $40.85 (+26.20% today).
What is Viking Therapeutics, Inc.'s market cap?
Viking Therapeutics, Inc. has a market capitalization of approximately $4.77B.
What is Viking Therapeutics, Inc.'s earnings per share (EPS)?
Viking Therapeutics, Inc.'s trailing twelve-month EPS is $-6.34.
Does Viking Therapeutics, Inc. pay a dividend?
Viking Therapeutics, Inc. does not currently pay a regular dividend.
What is Viking Therapeutics, Inc.'s 52-week trading range?
Over the past year, VKTX has traded between $24.78 and $43.15.
What is the analyst price target for Viking Therapeutics, Inc.?
The mean analyst price target for Viking Therapeutics, Inc. is $94.61. This is informational only and not investment advice.
Latest Viking Therapeutics, Inc. (VKTX) news
- Viking Therapeutics (VKTX) Reports VK2735 Trial Data, Is The Stock Fully Priced?News · Sep 23, 2026
- Why Viking Therapeutics Stock Skyrocketed on TuesdayNews · Sep 23, 2026
- VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?News · Sep 23, 2026
- Viking Therapeutics (VKTX) Rockets 35.7% After Weight Loss Drug Trial — What’s The Selling Point?News · Sep 22, 2026
- Lilly Rises Higher as Viking Preserves Up to 90% MonthlyNews · Sep 22, 2026
- VKTX Stock Jumps 36% As Oppenheimer Hikes Target, Peers Call Data A WinNews · Sep 22, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live VKTX dashboard…